Comparison of FLT3-LM incidence in de novo AML, t-AML, and s-AML
| Karyotype . | De novo n = 213 of 871 (24.5%) . | s-AML n = 12 of 77 (15.6%) . | t-AML n = 6 of 52 (11.5%) . |
|---|---|---|---|
| Normal | 149 of 379 (39.3%) | 8 of 33 (24.2%) | 5 of 13 (38%) |
| t(15;17) | 24 of 66 (36.4%) | — | −/2 |
| t(8;21) | 6 of 65 (9.2%) | — | −/4 |
| inv(16) | 0 of 46 | — | −/1 |
| t(11q23) | 1 of 34 (2.9%) | — | −/2 |
| Rare (t) | 1 of 19 (5.2%) | −/1 | −/3 |
| Complex | 2 of 94 (2.1%) | 1 of 14 (7.1%) | −/12 |
| − 5/− 7/7q− | 1 of 16 (6.3%) | −/7 | −/5 |
| Others | 29 of 152 (19.1%) | 3 of 22 (9.1%) | 1 of 10 (10%) |
| Karyotype . | De novo n = 213 of 871 (24.5%) . | s-AML n = 12 of 77 (15.6%) . | t-AML n = 6 of 52 (11.5%) . |
|---|---|---|---|
| Normal | 149 of 379 (39.3%) | 8 of 33 (24.2%) | 5 of 13 (38%) |
| t(15;17) | 24 of 66 (36.4%) | — | −/2 |
| t(8;21) | 6 of 65 (9.2%) | — | −/4 |
| inv(16) | 0 of 46 | — | −/1 |
| t(11q23) | 1 of 34 (2.9%) | — | −/2 |
| Rare (t) | 1 of 19 (5.2%) | −/1 | −/3 |
| Complex | 2 of 94 (2.1%) | 1 of 14 (7.1%) | −/12 |
| − 5/− 7/7q− | 1 of 16 (6.3%) | −/7 | −/5 |
| Others | 29 of 152 (19.1%) | 3 of 22 (9.1%) | 1 of 10 (10%) |